ArticleArchives of microbiology2025
The protective effect and mechanism of rhIFN-α1b on lung injury in mice infected with H1N1 influenza A virus.
Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recombinant human interferon-α1b (rhIFN-α1b) has shown proven antiviral and immunomodulatory effects in multiple viral infections. This study was designed to explore the protective effect and mechanism of rhIFN-α1b on lung injury in mice infected with influenza A virus (H1N1). The lung-adapted strain of influenza A virus NYMCX-179 A was inoculated into mice via intranasal infection, followed by administration of rhIFN-α1b. Mouse lung tissues exhibited significant inflammatory damage, enhanced HA expression, and distinct distribution of viral particles (observed by TEM). Administration of rhIFN-α1b or oseltamivir reduced mouse mortality, alleviated lung tissue inflammation, downregulated HA expression, decreased H1 mRNA levels, and attenuated the secretion of inflammatory cytokines. Moreover, the in vivo protective effect of rhIFN-α1b administered via nebulization was stronger than that of intramuscular injection. In vitro, rhIFN-α1b reduced inflammatory cytokine secretion, diminished HA protein and H1 mRNA levels, and inhibited apoptosis in H1N1 virus-infected MDCK cells. Mechanistically, rhIFN-α1b increased the protein levels of phosphorylated JAK2 (p-JAK2) and phosphorylated STAT3 (p-STAT3) in both H1N1 virus-infected MDCK cells and lung tissues from mice with lung injury. Additionally, treatment with AG490-a JAK/STAT signaling inhibitor-reversed the effects of rhIFN-α1b on HA expression, inflammatory cytokine secretion, and cell apoptosis in H1N1 virus-infected MDCK cells. These findings demonstrated that rhIFN-α1b ameliorates lung tissue damage in H influenza A virus (H1N1)-infected mice, with the protective effect of nebulized rhIFN-α1b being stronger than that of intramuscularly administered rhIFN-α1b. Furthermore, the protective effect of rhIFN-α1b is associated with the activation of the JAK/STAT signaling pathway.
Indexed as
Identifiers
41222720What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.